Scribe Therapeutics files for IPO to fund CRISPR cardiovascular therapies; terms not yet set

The company will offer shares in a primary offering (proceeds to the company), but the exact number is not yet disclosed in this preliminary filing. The blank indicates terms are still being finalized.

The company has granted underwriters a standard 30-day greenshoe option to purchase additional shares, though the exact number of shares subject to the option is not yet disclosed. If exercised, these additional shares would also be primary (proceeds to the company).

The total common stock outstanding after the offering is not yet disclosed, with separate counts depending on whether the underwriter option is exercised. These figures will determine dilution to existing shareholders once finalized.

Scribe has received Australian regulatory clearance and begun dosing patients in its first-in-human trial of STX-1150, its lead CRISPR-based LDL-cholesterol-lowering therapy, enrolling up to 64 adults with elevated LDL-C and cardiovascular risk. The company expects to report initial safety, tolerability, and efficacy data in the first half of 2027, marking a key clinical milestone for the company's transition from preclinical to clinical-stage development.

Scribe has secured up to approximately $25.7 million in non-dilutive grant funding from CIRM to advance its STX-1200 (elevated Lp(a)) and STX-1400 (elevated triglycerides) programs through preclinical development and manufacturing. With this support, the company anticipates initiating Phase 1 trials for one program as early as 2027 and the other in 2028, extending its clinical pipeline without additional equity dilution.

Since founding in 2017, Scribe has raised approximately $150 million in equity with only one dilutive round in the past four years, demonstrating capital discipline. The company has preserved ownership and optionality across its wholly-owned pipeline and collaboration programs while advancing multiple clinical-stage candidates, a track record that may appeal to investors concerned about dilution risk in early-stage biotech.

Scribe has received over $180 million in aggregate upfront, milestone, and reimbursement payments from its strategic collaborations with Sanofi (sickle cell disease and other genetic diseases) and Lilly (neurological and neuromuscular disorders). These partnerships provide non-dilutive funding, validate the company's CRISPR technologies across multiple therapeutic areas, and offer potential future milestone and royalty revenue streams.

The company states the PCSK9-based LDL-cholesterol-lowering market currently exceeds $5 billion annually but remains significantly underpenetrated, with fewer than 1% of eligible patients treated. Scribe positions STX-1150 as addressing adherence limitations of existing therapies (chronic dosing, high discontinuation rates) that contribute to this low penetration, framing a large addressable market opportunity if its one-time or durable dosing approach proves successful.

The filing states preliminary net proceeds figures (base and with full overallotment) but leaves the dollar amounts blank, pending final pricing. The figures are stated as net to the company after underwriting discounts and offering expenses.

The company plans to allocate a portion of net proceeds to its lead product candidate STX-1150, though the dollar amount and development milestone are left blank in this preliminary filing. This is the first named use of proceeds.

The company plans to allocate proceeds to two additional product candidates, STX-1200 and STX-1400, though the dollar amount and development milestones are left blank. These are the second and third named pipeline programs.

The company explicitly states that the IPO proceeds plus existing cash will not be sufficient to advance any program through regulatory approval, and that substantial additional capital will be required. This is a material disclosure about future funding needs.

The company provides a cash runway estimate (date left blank in this preliminary filing) based on existing cash plus IPO proceeds. This runway estimate is explicitly stated to be based on assumptions that may prove wrong.

The section discloses the dilution framework but all dollar amounts, share counts, and percentages are placeholders (blank fields). The actual dilution per share to new investors, pro forma net tangible book value figures, ownership percentages, and total consideration amounts will be filled in once the offering price range and share count are determined at pricing.

As of March 31, 2026, there are 6,993,919 shares issuable upon exercise of outstanding stock options at a weighted-average exercise price of $1.21 per share. Additional shares are reserved under the 2018 Plan (9,904,452 shares) which will become available under the 2026 Plan, plus additional shares to be reserved under the 2026 Plan and ESPP. Exercise of these options will cause further dilution to new investors beyond the dilution from the offering itself.

The company discloses substantial doubt about its ability to continue as a going concern. With $49.7 million in cash, cash equivalents and marketable securities as of March 31, 2026, management states it will not have sufficient cash to support operations for at least twelve months from the financial statement issuance date. This is a serious liquidity warning indicating the company must raise capital or face potential liquidation.

The company reports net losses of $47.8 million (2024), $21.8 million (2025), and $17.4 million for Q1 2026, with a cumulative accumulated deficit of $175.1 million as of March 31, 2026. The company has never generated product revenue and expects losses to continue for the foreseeable future as it advances clinical trials and development programs.

The company held $49.7 million in cash, cash equivalents and marketable securities as of March 31, 2026. Management states this amount, together with net proceeds from this offering, will fund operations through an unspecified date (blank in the filing). The going-concern disclosure indicates this cash is insufficient for twelve months without additional financing.

Scribe is a clinical-stage company founded in 2017 with no completed clinical trials and no products approved for commercial sale. All programs are in research, preclinical, or clinical stages with high risk of failure. The company has initiated clinical development of lead candidate STX-1150 and has preclinical programs STX-1200 and STX-1400, but has not yet demonstrated ability to complete clinical trials or obtain regulatory approvals.

The company's epigenetic silencing platform has shown only two years of durability in non-human primates, and human durability remains unproven. If epigenetic effects diminish over time in humans due to cellular processes, products may require re-dosing or provide only transient benefit, reducing commercial viability versus alternatives.

Despite engineering efforts to reduce off-target gene edits, the company has not yet tested ELXR and XE in clinical trials. Off-target modifications or unintended on-target consequences could cause serious adverse events, delay or halt development, and trigger extended regulatory follow-up periods of up to 15 years per FDA guidance.

The company depends on collaborations with Sanofi and Lilly for development and commercialization, with limited control over partner resource allocation. Partners may de-emphasize programs, terminate agreements, or shift strategic focus, and any termination could make finding replacement collaborators difficult and delay or end development programs.

The company expects its gene-editing therapies to carry substantial per-administration costs, and commercial success depends on government and private payer willingness to cover and reimburse high prices. Payors may refuse coverage or limit reimbursement levels, and obtaining coverage is a time-consuming, costly process with uncertain outcomes that could prevent successful commercialization even if products are approved.

The company reported a net loss of $17.4 million for the three months ended March 31, 2026, compared to a net loss of $3.4 million in the same period of 2025. The loss increased by $13.9 million (406%) primarily due to a $14.9 million decrease in collaboration revenue (from $17.1M to $2.2M) driven by a non-recurring milestone achieved in Q1 2025, and a $6.0 million unfavorable swing in the fair value adjustment of the convertible note.

The company held $49.7 million in cash, cash equivalents, and investments as of March 31, 2026. Management states that existing cash plus IPO proceeds will fund operations through an unspecified date (blank in the filing). The company acknowledges it will need to raise substantial additional capital beyond that point to finance operations.

The company has initiated its first-in-human clinical trial for lead product candidate STX-1150 in Australia, enrolling up to 64 adults with elevated LDL cholesterol. Initial safety, tolerability, and efficacy data are expected in the first half of 2027. This marks the company's transition from preclinical to clinical-stage development.

Collaboration revenue fell 87% from $17.1 million in Q1 2025 to $2.2 million in Q1 2026. The decline was driven by a non-recurring milestone payment and expiration of substitution rights under the Lilly agreement in Q1 2025, plus completion of Sanofi workplan activities. The company's revenue is entirely from collaboration agreements and will fluctuate based on milestone timing.

The company disclosed substantial doubt about its ability to continue as a going concern. As of March 31, 2026, it had $49.7 million in cash and cash equivalents against $40.5 million in outstanding debt and a $175.1 million accumulated deficit. The company states that its existing cash plus IPO proceeds will fund operations through an unspecified date (blank in the filing).

For the three months ended March 31, 2026, the company reported a net loss of $17.4 million. This compares to a net loss of $3.4 million in the same period of 2025, representing a significant increase in quarterly losses.

The $30.0 million Lilly Note plus $7.8 million in accrued interest automatically converted into approximately 6.25 million shares of common stock at maturity on May 11, 2026. No cash was paid. This conversion eliminated the $40.5 million debt balance referenced as of March 31, 2026.

The company has accumulated losses of $175.1 million since inception. This reflects the company's pre-revenue, clinical-stage status and ongoing investment in research and development. The company does not expect to generate product revenue unless and until it successfully develops and obtains approval for a product candidate.

The company has begun its first human trial of STX-1150 (an epigenetic PCSK9 silencer for LDL cholesterol lowering) in Australia, enrolling up to 64 adults with elevated LDL-C. Initial safety and efficacy data are expected in the first half of 2027. This is the company's first clinical-stage asset and marks the transition from preclinical to human testing.

The company has secured up to $25.7 million in non-dilutive grant funding from CIRM to advance its STX-1200 (Lp(a) lowering) and STX-1400 (triglyceride lowering) programs. This funding supports preclinical development and manufacturing, with Phase 1 trials planned for 2027 and 2028. Non-dilutive capital extends the company's runway and validates the programs' scientific merit.

The company has received over $180 million in aggregate payments from its strategic collaborations with Sanofi (rare genetic diseases including sickle cell) and Lilly (neurological/neuromuscular disorders). These payments include upfront fees, milestones, and expense reimbursements, demonstrating commercial validation of the platform and providing non-dilutive capital to fund internal programs.

Since founding in 2017, the company has raised approximately $150 million in equity with only one dilutive round in the past four years. Management emphasizes capital efficiency and retention of ownership/optionality. Investors should note that the company has operated on relatively modest equity capital (supplemented by $180 million in collaboration payments and $25.7 million in CIRM grants), but will likely require substantial additional capital to advance multiple clinical programs.

The company has begun a Phase 1 trial in Australia enrolling up to 64 patients with elevated LDL cholesterol. The trial is open-label, single ascending dose followed by expansion, starting at 20 mg. Primary endpoint is safety/tolerability; secondary endpoints include LDL-C and PCSK9 reduction. Initial data expected in first half of 2027.

In non-human primates, a single 0.75 mg/kg dose of the STX-1150 prototype maintained greater than 50% LDL cholesterol reduction for two years. This durability is central to the company's thesis that a one-time treatment can replace chronic dosing (statins, PCSK9 inhibitors) which suffer 20–60% one-year discontinuation rates in the real world.

In a human-LPA knock-in mouse model, 0.2–0.4 mg/kg of the STX-1200 prototype achieved ~70% on-target editing and greater than 90% Apo(a) reduction. At 0.4 mg/kg, STX-1200 showed approximately $400 billion four times greater editing potency than a reference Cas9. In cynomolgus monkeys, a single dose achieved greater than 80% liver editing and greater than 95% plasma Apo(a) reduction. No off-target edits were detected in primary human hepatocytes at 10x supersaturating dose.

The company states it expects to start a Phase 1 trial for one of its two lead programs (STX-1200 for Lp(a) or STX-1400 for triglycerides) as early as 2027, with the second program following in 2028. Both programs are currently in preclinical development and are supported by funding from the California Institute for Regenerative Medicine (CIRM). This timeline is preliminary and contingent on successful completion of preclinical work.